Mercodia oxidized LDL ELISA is a unique sandwich ELISA based on the proprietary mouse monoclonal antibody 4E6, which is directed against a conformational epitope in oxidized ApoB-100. Elevated plasma levels of oxidized LDL are associated with higher cardiovascular risk and higher incidence of metabolic diseases, i.e. metabolic syndrome, obesity and type 2 diabetes. Also sub-clinical atherosclerosis, kidney and liver diseases are associated with increased levels of oxidized LDL.
Read the Directions for Use
The Mercodia Oxidized LDL ELISA kit is intended to be used for the in vitro quantitative measurement of oxidized low density lipoproteins (oxidized LDL) in human serum or plasma. Lipoprotein measurements are used in the diagnosis and treatment of lipid disorders (such as diabetes mellitus), atherosclerosis, and various liver and renal diseases.
Format: 1 x 96 wells
Samples: Serum, plasma
Sample volume: 25 μL
Assay range: 1.4-22.5 mU/L
Detection limit: ≤ 1 mU/L
Incubation: (min) 120+60+15
The detection limit is ≤ 1 mU/L calculated as three standard
deviations above the Calibrator 0.
Recovery upon addition is 85 - 107 % (95 %).
Each sample was analyzed in 3 - 8 replicates on 20 different
|Sample||Mean Value||Coefficient of variation|
|(μg/L)||within assay %||between assay %||total assay %|
The recommended sample type in the Mercodia Oxidized
LDL ELISA is fresh EDTA-plasma. Serum or heparin plasma
may also be used.
Grossly lipemic, icteric or hemolyzed samples do not interfere
in the assay.
Mercodia Oxidized LDL ELISA is a solid phase two-site enzyme immunoassay based on the sandwich technique, in which two monoclonal antibodies are directed against separate antigenic determinants on the oxidized apolipoprotein B molecule.
Oxidized LDL in the sample reacts with anti-oxidized LDL antibodies bound to microtitration wells and peroxidase-conjugated anti-oxidized LDL antibodies in the solution.
Summary of protocol
Know what you measure
Mercodia has developed the Mercodia Oxidized LDL ELISA based on the proprietary mouse monoclonal antibody 4E6, developed by professors Holvoet and Collen at the University of Leuven in Belgium. The monoclonal antibody 4E6 is directed against a conformational epitope in the ApoB100 moiety of LDL that is generated as a consequence of substitution of at least 60 lysine residues of Apo B100 with aldehydes (Holvoet 2004). This number of substituted lysines corresponds to the minimal number required for scavenger-mediated uptake of oxidized LDL. Substituting aldehydes can be produced by peroxidation of lipids of LDL, resulting in the generation of oxidized LDL. However, lipid peroxidation is not required. Indeed, aldehydes that are released by endothelial cells under oxidative stress or by activated platelets may also induce the oxidative modification of Apo B100 in the absence of lipid peroxidation of LDL. The unique affinity of the antibody 4E6 used in the Mercodia Oxidized LDL ELISA makes it possible to measure both MDA and aldehyde modified oxidized LDL, which sets this assay apart from assays based on other antibodies.
Kaikkonen, J, E, Kresanov, P (2014)
High serum n6 fatty acid proportion is associated with lowered LDL oxidation and inflammation: The Cardiovascular Risk in Young Finns Study
Lerman, R, H, Desai, A (2014)
A Phytochemical-rich Multivitamin-multimineral Supplement Is Bioavailable and Reduces Serum Oxidized Low-density Lipoprotein, Myeloperoxidase, and Plasminogen Activator Inhibitor-1 in a Four-week Pilot trial of Healthy Individuals
Verhoeven, V, Van der Auwera, A, Van Gaal, L (2015)
Can red yeast rice and olive extract improve lipid profile and cardiovascular risk in metabolic syndrome?: a double blind, placebo controlled randomized trial